ContraVir Pharmaceuticals competitors

ContraVir Pharmaceuticals's competitors include MyoKardia, Athersys, Otonomy and Ironwood Pharmaceuticals
Add company...
ContraVir Pharmaceuticals
ContraVir is a biopharmaceutical company focused on the clinical development of TXL and CRV431 to treat Hep B and Valnivudine to treat PHN.
MyoKardia
MyoKardia discovers, develops and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.
Athersys
Athersys, a biopharmaceutical company, discovers and develops therapeutic products for the treatment of several disease indications.
Otonomy
Otonomy is a biopharmaceutical company developing and commercializing treatments for diseases of the inner and middle ear.
Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, an entrepreneurial pharmaceutical company, develops drugs for gastrointestinal and cardiovascular diseases.
Founding Date
Founding Date
2013
Founding Date
2012
Founding Date
1995
Founding Date
2008
Founding Date
N/A
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Edison, US HQ
Edmonton, CA
Doylestown, US
Locations
South San Francisco, US HQ
Locations
Cleveland, US HQ
Canton, US
Locations
San Diego, US HQ
Locations
Cambridge, US HQ
Employees
Employees
14
Employees
1024% increase
Employees
60
Employees
139
Employees
674
Valuation ($)
Valuation ($)
9.2 m
Valuation ($)
2.6 b
Valuation ($)
257.8 m
Valuation ($)
79.6 m
Valuation ($)
2.6 b
Facebook likes
Facebook likes
N/A
Facebook likes
N/A
Facebook likes
475
Facebook likes
1.1 k
Facebook likes
18
Twitter followers
Twitter followers
517
Twitter followers
387
Twitter followers
953
Twitter followers
267
Twitter followers
3.1 k

Financial

Revenue (est.)
Revenue (est.)
N/A
Revenue (est.)
$22.5m (FY, 2017)
Revenue (est.)
$3.7m (FY, 2017)
Revenue (est.)
$1.2m (FY, 2017)
Revenue (est.)
$274m (FY, 2016)
Net income
Net income
($17m) (FY, 2016)
Net income
($46m) (FY, 2017)
Net income
N/A
Net income
($90.1m) (FY, 2017)
Net income
($81.7m) (FY, 2016)

Operating

Patents (US)
Patents (US)
N/A
Patents (US)
4 (FY, 2017)
Patents (US)
21 (FY, 2016)
Patents (US)
N/A
Patents (US)
N/A
Patents Issued
Patents Issued
N/A
Patents Issued
N/A
Patents Issued
200 (FY, 2016)
Patents Issued
88 (FY, 2016)
Patents Issued
N/A
Phase I Trials Products
Phase I Trials Products
N/A
Phase I Trials Products
2 (FY, 2017)
Phase I Trials Products
N/A
Phase I Trials Products
1 (FY, 2016)
Phase I Trials Products
N/A
Phase II Trials Products
Phase II Trials Products
N/A
Phase II Trials Products
1 (FY, 2017)
Phase II Trials Products
N/A
Phase II Trials Products
2 (FY, 2016)
Phase II Trials Products
N/A
Preclinical Phase Products
Preclinical Phase Products
N/A
Preclinical Phase Products
3 (FY, 2017)
Preclinical Phase Products
N/A
Preclinical Phase Products
1 (FY, 2016)
Preclinical Phase Products
N/A

Funding

Total funding raised
Total funding raised
N/A
Total funding raised
$ 98m
Total funding raised
$ 9m
Total funding raised
$ 153.4m
Total funding raised
$ 284m
For sources of this data, please see the company profileDownload Excel

View company profiles

MyoKardia
HQ
South San Francisco, US
Employees
102↑ 4% increase

MyoKardia discovers, develops and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.

View company
Athersys
HQ
Cleveland, US
Employees
60

Athersys, a biopharmaceutical company, discovers and develops therapeutic products for the treatment of several disease indications.

View company
Otonomy
HQ
San Diego, US
Employees
139

Otonomy is a biopharmaceutical company developing and commercializing treatments for diseases of the inner and middle ear.

View company
Ironwood Pharmaceuticals
HQ
Cambridge, US
Employees
674

Ironwood Pharmaceuticals, an entrepreneurial pharmaceutical company, develops drugs for gastrointestinal and cardiovascular diseases.

View company